Literature DB >> 8160253

Probable metabolic interaction between methadone and fluvoxamine in addict patients.

G Bertschy1, P Baumann, C B Eap, D Baettig.   

Abstract

We report five cases where fluvoxamine (FLVX) was added to maintenance treatment with methadone (MTD) in addict patients with affective disorders. In view of the implication of FLVX in several metabolic drug interactions, MTD plasma levels were measured before and after treatment with FLVX. A slight increase (approximately 20% of the MTD plasma level/dose ratio) occurred in two cases. In the remaining three patients, the interaction was more pronounced (40-100% increase of the MTD plasma level/dose ratio), with clinical manifestations of opiate withdrawal after stopping FLVX therapy in one case. Caution is needed when starting or stopping treatment with FLVX in patients receiving maintenance treatment with methadone.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8160253     DOI： 10.1097/00007691-199402000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


  11 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 4.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 5.  Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.

Authors:  S M Cheer; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Drug interactions of clinical significance with selective serotonin reuptake inhibitors.

Authors:  P B Mitchell
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

Review 7.  Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

Authors:  Elinore F McCance-Katz; Lynn E Sullivan; Srikanth Nallani
Journal:  Am J Addict       Date:  2010 Jan-Feb

Review 8.  Fluvoxamine. A review of global drug-drug interaction data.

Authors:  W Wagner; E W Vause
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of fluvoxamine.

Authors:  E Perucca; G Gatti; E Spina
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

10.  A population-based study of concurrent prescriptions of opioid analgesic and selective serotonin reuptake inhibitor medications during pregnancy and risk for adverse birth outcomes.

Authors:  Ayesha C Sujan; Martin E Rickert; Patrick D Quinn; Christina Ludema; Kelsey K Wiggs; Henrik Larsson; Paul Lichtenstein; Catarina Almqvist; Anna Sara Öberg; Brian M D'Onofrio
Journal:  Paediatr Perinat Epidemiol       Date:  2020-12-22       Impact factor: 3.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.